New study: can a biologic drug outperform standard therapy for Crohn's from the start?
NCT ID NCT07659353
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This study compares two treatment strategies for people newly diagnosed with moderate-to-severe Crohn's disease. One group gets mirikizumab (a biologic) right away, while the other gets the standard approach of azathioprine plus steroids. The goal is to see which leads to deep remission at 52 weeks. 320 adults aged 18-75 who have not used these drugs before will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Schleswig-Holstein
Kiel, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mirikizumab (a biologic antibody) and azathioprine (an immunosuppressant)
What this could lead to
If successful, this could show that starting with mirikizumab right away is more effective than the current standard therapy for controlling Crohn's disease.
What could go wrong
This is an open-label trial, so results may be biased. It's also a Phase 4 study, meaning mirikizumab is already approved; the main question is about timing, not a cure. Some patients may not respond or may experience side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.